Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 2 Small Cell Lung Carcinoma 1 Recurrence 1 Neoplasm Metastasis 1 Melanoma 1 Lung Neoplasms 1 Gliosarcoma 1 Gastrointestinal Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Brain Neoplasms 1

Interventions

Dexamethasone 29 Cyclophosphamide 21 Rituximab 17 Cytarabine 16 Bortezomib 13 Gemcitabine 12 fludarabine 11 Methotrexate 11 Lenalidomide 10 Filgrastim 10 Vincristine 9 Etoposide 9 pomalidomide 8 pembrolizumab 8 Paclitaxel 8 Azacitidine 8 venetoclax 7 carfilzomib 7 Doxorubicin 7 Docetaxel 7 Cyclosporine 7 Calcium Dobesilate 7 Antilymphocyte Serum 7 fludarabine phosphate 6 Topotecan 6 Temozolomide 6 Radiotherapy 6 Peripheral Blood Stem Cell Transplantation 6 Mitoxantrone 6 daratumumab 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Recurrence × Memantine × Clear all

NCT01260467 2015-12-10

Memantine for Recurrent Glioblastoma

University of Rochester

Phase 2 Terminated

4 enrolled 3 charts

Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡